Advanced Filters
noise

hematologic-cancer Clinical Trials

A listing of hematologic-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 344 clinical trials
T Thomas Bert

Hypnosis: a Path to Appeasement

Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with …

18 years of age All Phase N/A
C Clementine MAHAUT

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs. The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell …

2 years of age All Phase N/A
M Marina Hernández Aliaga

Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy

The goal of this clinical trial is to learn if two non-pharmacological strategies can help reduce neurotoxicity caused by CAR-T cell therapy in adult patients with hematologic cancer, both sexes, aged 18 to 80 years. The strategies are: A structured physical activity program. A combination of physical activity and nutritional …

18 - 80 years of age All Phase N/A
S Sandra E L T Pitter, MD

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Aims To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on …

18 years of age All Phase N/A
P Pier Luigi Zinzani, MD

Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Patients undergoing particular intensive and (sub)myeloablative chemotherapy regimens with subsequent autologous stem cell transplant currently have a relatively low rate of therapy-related complications, both infectious and non-infectious (organ damage), and can therefore benefit from a specific multidisciplinary care programme at home. In this clinical context, early discharge and domicile of …

18 - 75 years of age All Phase N/A

Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy

It is a study about adaptated physical activity for patients receiving a stem cell transplantation. They will benefit of 6 adaptated individuals lessons at home between 1 month and 3 months after stem cell transplantation. The study's goal is to observe if adaptated activity has an positive impact on weight …

18 years of age All Phase N/A
L Luxiang Wang

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT

To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.

18 - 75 years of age All Phase 3
S Shuhua Yi, Dr.

The Study of ICP-248 in Patients With Mature B-cell Malignancies

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.

18 - 80 years of age All Phase 1
X Xunlei Kang, MD.PhD

Membrane Target Detection for Leukemia Treatment

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been …

18 years of age All Phase N/A
F Francesca Bonifazi, MD

Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion

In recent years, the application of increasingly advanced methods of ex-vivo cell culture and cell engineering has made it possible to develop new cellular therapeutic platforms including the "CAR (Chimeric Antigen Receptor) - T cell therapy". CAR-T cell therapy is a therapy that uses T lymphocytes engineered to express a …

18 - 70 years of age All Phase N/A

Simplify language using AI